Ada Azaryan

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 337 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

Peter Schäfer, Alan Kivitz, Jianglin Ma et al. · Rheumatology and Therapy · 2019 · 66 citations · Full text

Medicine, Immunology, Pharmacology +17

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, Wael A. Harb, Brian T. Hill et al. · Blood · 2013 · 45 citations

Medicine, Oncology, Pharmacology +13

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella J. Lugtenburg, Rogier Mous, Michael Roost Clausen et al. · Blood · 2019 · 19 citations

Medicine, Immunology, Oncology +13

Melanoma epidemiology, prognosis and trends in Latvia

Kristīne Azarjana, Aija Ozola, Dace Ruklisa et al. · Journal of the European Academy of Dermatology and Venereology · 2012 · 18 citations · Full text

Medicine, Dermatology, Oncology +16